Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next ...
10d
The event will be webcast live and may be accessed via a link in the Investors section of the Nurix website. The archived webcast will be available for 30 days after the event. About Nurix ...
The strong performance of NX-5948 has bolstered confidence in Nurix's protein degradation platform. Analysts note that the early Progression-Free Survival (PFS) curves for BTK degraders appear ...
The strong performance of NX-5948 has bolstered confidence in Nurix's protein degradation platform. Analysts note that the early Progression-Free Survival (PFS) curves for BTK degraders appear ...
The BRAF Inhibitors market is expected to grow significantly in the coming years. This is due to the increasing number of patients being diagnosed with cancer, rise in biomarker testing rates, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback